16 Biotechnology Stocks to Buy Now

Advertisement

This week, 16 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, BioSpecifics Technologies Corp. (BSTC) pushes up from a B to a A rating. BioSpecifics Technologies Corp. is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. The company also gets A’s in sales growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of BSTC stock.

Isis Pharmaceuticals, Inc. (ISIS) boosts its rating from a C to a B this week. Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ISIS stock.

The rating of Newlink Genetics Corporation (NLNK) moves up this week, rising from a B to a A. Newlink Genetics Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The company also gets A’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NLNK stock.

This is a strong week for Emergent BioSolutions Inc. (EBS). The company’s rating climbs to A from the previous week’s B. Emergent BioSolutions Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The company also gets A’s in operating margin growth, earnings growth, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EBS stock.

Ardelyx, Inc. (ARDX) improves from a C to a B rating this week. The company also gets A’s in sales growth, earnings growth, and earnings revisions. For more information, get Portfolio Grader’s complete analysis of ARDX stock.

Cellular Biomedicine Group, Inc. (CBMG) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of CBMG stock.

TG Therapeutics, Inc. (TGTX) shows solid improvement this week. The company’s rating rises from a C to a B. TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of TGTX stock.

ImmunoGen, Inc.’s (IMGN) ratings are looking better this week, moving up to a B from last week’s C. ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of IMGN stock.

Galmed Pharmaceuticals Ltd. (GLMD) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of GLMD stock.

Calithera Biosciences, Inc. (CALA) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of CALA stock.

This week, AmpliPhi BioSciences Corporation’s (APHB) ratings are up from a C last week to a B. The company also gets A’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APHB stock.

Progenics Pharmaceuticals, Inc. (PGNX) shows solid improvement this week. The company’s rating rises from a C to a B. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

This week, Catalyst Biosciences, Inc.’s (CBIO) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of CBIO stock.

The rating of ContraFect Corp (CFRX) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of CFRX stock.

Biocept, Inc. (BIOC) earns a B this week, jumping up from last week’s grade of C. Biocept, Inc. is a global provider of clinical trials services, providing medical image management and eClinical services, including electronic data capture and clinical data management solutions. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of BIOC stock.

AVEO Pharmaceuticals, Inc. (AVEO) gets a higher grade this week, advancing from a C last week to a B. AVEO Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of AVEO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/10/16-biotechnology-stocks-to-buy-now/.

©2024 InvestorPlace Media, LLC